KEY BENEFITS AND USES

  • Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.
  • Drill down into physicians’ treatment sequences and understand which drugs to position against or how to defend share.
  • Identify untapped treatment scenarios and key competitors to aid trial design.
  • Evaluate unique disease-specific treatment patterns and dynamics to plan and manage sales and marketing resources, and execute commercialization messages.
  • Discover untapped populations to expand product share and drive strategic decisions.

QUESTIONS ANSWERED

  • Where is my product positioned versus competitors’ products in the treatment journey?
  • What are physicians’ most frequent treatment sequences? Who is benefiting, and how can I defend my asset’s share and position?
  • What are the market-relevant treatment scenarios, according to oncology experts?
  • Where are the untapped business opportunities on which I can capitalize?
  • How can I optimize trial design and ensure a competitive edge for my pipeline asset?

PRODUCT DESCRIPTION

Treatment Sequencing provides disease-specific, sequential treatment patterns in market-relevant treatment scenarios and drug share mapped to the treatment journey. The quantitative sequencing analysis illuminates drug positioning through primary market research-based insights from physicians.

GEOGRAPHIES

United States

PRIMARY MARKET RESEARCH

Survey of ~100 U.S. physicians

Table of contents

  • Bladder Cancer - Current Treatment - Detailed, Expanded Analysis: Treatment Sequencing (US)
    • Treatment Sequencing Bladder Cancer US June 2020

Author(s): Vandana, M.Pharm

Vandana is a Research Associate in the oncology team at Decision Resources Group. Her current work is focused on performing market research in several oncology indications across the major pharmaceutical markets.

Prior to joining DRG, she worked as a Business Analyst (Digital marketing) at Iquanti, Bangalore. She has also previously worked as Analyst in WNS, Noida, India. She has worked on multiple client projects involving competitive intelligence, forecasting, pipeline analysis, keywords research and product/company profiling. She has earned her Master's in Pharmacology from DIPSAR, New Delhi, India.


Related Reports

Bladder Cancer - Landscape & Forecast - Disease Landscape & Forecast

The 2016/17 FDA approvals of five immune checkpoint inhibitors for platinum-treated patients have significantly altered the treatment landscape for advanced bladder cancer, which has historically b...

View Details

Bladder Cancer - Current Treatment - Detailed, Expanded Analysis: Physician Insights (US)

The bladder cancer market has seen a tremendous uptake of immune checkpoint inhibitors with their approval in the locally advanced / metastatic setting and, in the case of Merck & Co.’s K...

View Details

Bladder Cancer - Epidemiology - Extrapolated Worldwide Coverage

DRG’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key bladder cancer patient...

View Details

Bladder Cancer - Epidemiology - Mature Markets

Decision Resources Group Epidemiology's coverage of bladder cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and pre...

View Details